MolDx Program
A Medicare molecular diagnostics program, administered by Palmetto GBA and adopted by several Medicare Administrative Contractors, that technically assesses molecular tests and assigns Z-codes for claims processing and local coverage.
Definition
The MolDx (Molecular Diagnostic Services) Program is a Medicare Administrative Contractor initiative, originally developed by Palmetto GBA and now used by multiple MACs including Noridian and CGS, that establishes coverage, coding, and pricing methodologies specific to molecular and genomic diagnostic tests billed to Medicare. Laboratories register their tests with MolDx and receive a unique test identifier known as a Z-code, which is required for claims submission and allows the program to track individual proprietary tests separately from generic CPT codes that would otherwise obscure which specific assay was performed. MolDx conducts a technical assessment (TA) of each registered test's analytical and clinical validity, and, where a Local Coverage Determination (LCD) exists for that test category, the technical assessment findings feed into whether Medicare will cover the test for its Medicare Administrative Contractor jurisdiction.What this means in practice
For molecular diagnostic and genomic test developers, MolDx registration and Z-code assignment is typically a prerequisite to reimbursement in MolDx-participating MAC jurisdictions, functioning alongside, and sometimes overlapping with, PAMA private payor rate reporting and FDA regulatory status. Because MolDx LCDs are jurisdiction-specific rather than a single national policy, a test's coverage status can differ across MAC jurisdictions until CMS or the MACs harmonize policy, which laboratories must track separately from FDA clearance or approval status.- •Assuming a Z-code alone guarantees Medicare payment; the code enables claims tracking, but coverage still depends on whether an applicable LCD covers the specific test and clinical indication.
- •Treating MolDx technical assessment approval as equivalent to FDA clearance or approval; MolDx TA is a payor-driven evidentiary review distinct from FDA's premarket regulatory pathways.
- •Overlooking that MolDx policies vary by MAC jurisdiction, so a test covered in one region may lack an active LCD, and therefore reimbursement certainty, in another.
Frequently asked questions
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsLocal and National Coverage Determinations from Medicare.
Medicare coverage policies issued nationally (NCD) or by individual MAC contractors (LCD).
Real-world evidence used to support coverage and payment decisions.
IVD that identifies patients who will benefit from a specific drug.
More in Reimbursement
· Same categoryFederal program providing discounted drugs to safety-net providers.
The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient.
Migration of procedures from hospitals to ambulatory surgery centers.
Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.
Where this term appears across MedTech Terms.
Sources
3 sourcesEvery citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
- 1CMS, Local Coverage Determination ProcessTier 2 UncheckedCMScms.gov
- 2Palmetto GBA MolDx ProgramTier 4 UncheckedPalmetto GBApalmettogba.com
- 3CMS, Protecting Access to Medicare Act (PAMA) RegulationsTier 2 UncheckedCMScms.gov
Inline markers like [1] jump to the matching reference above.